Professional Documents
Culture Documents
Further Reading For 'America's Monopoly Moment'
Further Reading For 'America's Monopoly Moment'
Labor Unions and the Sherman Act: Rethinking Labor 's Nonstatutory
Exemption
Joseph L. Greenslade, Loyola of Los Angeles Law Review
To what extent should labor unions be subject to proscriptions of the Sherman Act?'
This question has generated much confusion and controversy amongst the legal
community. It has been the subject of heated debate since the Sherman Act was
passed in 1890.2 After almost one hundred years, however, courts have done very
little to clarify the confusion. The problem is two-fold. First, the antitrust laws3 and
the national labor laws4 embody two important, but at times conflicting,'
congressional declarations of public policy. On the one hand, the antitrust laws
strive to create and maintain a freely competitive commercial environment.6 On the
other hand, the national labor laws seek to improve employment conditions by
eliminating competition in the labor market over wages, hours and working
conditions. This conflict creates confusion for labor unions in determining how far
they can go, under the national labor laws, before they run afoul of the antitrust
laws.
Beware the Fine Print- A three part series about forced arbitration clauses
by the New York Times
Part 1: Arbitration Everywhere, Stacking the Deck of Justice
Jessica Silver-Greenberg & Robert Gebeloff, The New York Times
By inserting individual arbitration clauses into a soaring number of consumer and
employment contracts, companies like American Express devised a way to
circumvent the courts and bar people from joining together in class-action lawsuits,
realistically the only tool citizens have to fight illegal or deceitful business practices.
VCs raise less cash to fund Silicon Valleys next big thing
Marisa Kendall, The Mercury News
The venture capitalists who fuel Silicon Valleys tech ecosystem raised less cash last
quarter, slowing the frenzied flow of dollars gushing into the industry. Those
numbers show that deals keep getting bigger, but fewer companies are getting a
piece of the pie. Thats because investors are chasing big names like Uber and
Airbnb, hoping for a massive payout, said Paul Hsiao, co-founder and General
Partner of Canvas Ventures. New York-based WeWork, for example, closed a massive
$3 billion round in August, and that alone accounted for 17 percent of the quarters
overall investment into U.S. VC-backed companies, according to the Venture Monitor
report.
Dirty Medicine
Mariah Blake, Washington Monthly
This is hardly the first time Shaw has found his path to market blocked. In fact, he
has spent the last fifteen years watching his potentially game-changing inventions
collect dust on warehouse shelves. And the same is true of countless other small
medical suppliers. Their plight is just the most visible outgrowth of the tangled
system hospitals use to purchase their suppliesa system built on a seemingly
minor provision in Medicare law that few people even know about. Its a system that
has stifled innovation and kept lifesaving medical devices off the market. And while
its supposed to curb prices, it may actually be driving up the cost of medical
supplies, the second largest expenditure for our nations hospitals and clinics and a
major contributor to the ballooning cost of health care, which consumes nearly a
fifth of our gross domestic product.
It's official: Pharma mergers hurt innovation, and not only for the
dealmakers
Tracy Staton, FiercePharma
Our results very clearly show that R&D and patenting within the merged entity
decline substantially after a merger, compared to the same activity in both
companies beforehand, the authors, Justus Haucap and Joel Stiebale, wrote in the
HBR. Thats to be expected, the authors posit, because merger-minded
companies often target rivals with similar pipeline assets, to gain strength in
particular drug markets. But heres what else the authors found: On average,
patenting and R&D expenditures of non-merging competitors also fell--by more than
20%--within four years after a merger. Therefore, pharmaceutical mergers seem to
substantially reduce innovation activities in the relevant market as a whole.
Productivity Growth